Why the study?
It was unknown whether baseline heart rate variability analysis assessing autonomic nervous system activity could predict dexmedetomidine-induced bradycardia and hypotension during procedural sedation.
Does baseline heart rate variability predict dexmedetomidine-induced bradycardia and hypotension in adult patients undergoing ophthalmic surgery?
Does baseline heart rate variability predict dexmedetomidine-induced bradycardia and hypotension in adult patients undergoing ophthalmic surgery?
Baseline autonomic tone assessed by heart rate variability does not predict the hemodynamic side effects (bradycardia and hypotension) of dexmedetomidine sedation.
Answers are grounded in this paper and cite their sources.
Baseline HRV does not predict dexmedetomidine bradycardia or hypotension; leaves open reliable risk stratification beyond pre-drug SBP.
Dexmedetomidine, a central α-2 agonist, is used for procedural sedation and for conscious sedation influences on heart rate and blood pressure. Authors verified whether it is possible to predict bradycardia and hypotension with the use of heart rate variability (HRV) analysis for an autonomic nervous system (ANS) activity assessment. The study included adult patients of both sexes with an ASA score of I or II scheduled for ophthalmic surgery to be performed under sedation. The loading dose of dexmedetomidine was followed by a 15 min infusion of the maintenance dose. The frequency domain heart rate variability parameters from the 5-min Holter electrocardiogram recordings before dexmedetomidine administration were used for the analysis. The statistical analysis also included pre-drug heart rate and blood pressure as well as patient age and sex. The data from 62 patients were analysed. There was no relationship between the decrease in heart rate (42% of cases) and initial HRV parameters, haemodynamic parameters or sex and age of patients. In multivariate analysis, the only risk factor for a decrease in mean arterial pressure (MAP) > 15% from the pre-drug value (39% of cases) was the systolic blood pressure before dexmedetomidine administration as well as for a >15% decrease in MAP sustained at more than one consecutive time point (27% of cases). The initial condition of the ANS did not correlate with the incidence of bradycardia or hypotension; HRV analysis was not helpful in predicting the abovementioned side effects of dexmedetomidine.
No takes yet. Share an insight, caveat, or question.
Wujtewicz et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: